Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + propranolol
- Development stage
- Phase 3
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Ophthalmic
01
Overview
bevacizumab + propranolol is an investigational combination therapy being developed by Shahid Beheshti University of Medical Sciences for the treatment of wet age-related macular degeneration (wet AMD). This combination therapy utilizes the synergistic potential of bevacizumab, a humanized monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), and propranolol, a non-selective beta-adrenergic receptor antagonist. While bevacizumab is a standard-of-care anti-VEGF agent that prevents the growth of abnormal blood vessels in the retina, propranolol is hypothesized to further suppress neovascularization by blocking beta-adrenergic receptors, which are involved in the regulation of pro-angiogenic factors. The combination is administered via intravitreal injection and has been evaluated in clinical trials (such as the BEVALOL study) to determine if it offers superior efficacy in improving visual acuity and reducing macular edema compared to bevacizumab monotherapy.
- Other names
- Combined intravitreal bevacizumab and propranololBevacizumab/propranolol combination
02
Targets
Beyond the preview
Go deeper on bevacizumab + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + propranolol.